Sight Sciences, Inc.
SGHTHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframeSight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in. With a market capitalization of $495.2M, it sits in small-cap territory. The company operates in two segments, Surgical Glaucoma and Dry Eye.
Market Cap
$495.2M
Beta
2.45
P/E (TTM)
—
P/E (Fwd)
-22.47
EPS (TTM)
$-0.55
EPS (Fwd)
$-0.40
ROE
-48.4%
ROA
-10.8%
Cash
$79.8M
Total Debt
$42.0M
Free CF
-$8.6M
52W Change
70.3%
Annual Financials
Cash vs Debt
Where SGHT stands vs its 150-day and 200-day moving averages
As of the October 7, 2026 close, SGHT finished 50.44% above its 150-day moving average ($5.69) and 45.08% above its 200-day moving average ($5.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SGHT overbought or oversold?
At the October 7, 2026 close, SGHT's RSI(14) was 56.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $79.8M in cash and $42.0M in debt, SGHT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$8.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -48.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $71.3M (2022) to $77.4M (2025).
Sight Sciences, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Sight Sciences, Inc.'s trajectory.